Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · technology

Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as ...

6 August 2026 · By · Wire by Fusion42

Published

6 August 2026

Topic

technology

◆ Sectors

Biotech

◆ Source

Read at insilico.com →

◆ Verified

Fusion42 · 30 August 2026 · Fusion42 review

Insilico Medicine has nominated ISM9077, a potential first-in-class AI-designed Target Y inhibitor, as a preclinical candidate for treating ocular diseases, inflammatory disorders, and aging. The candidate showed superior efficacy and safety in preclinical models and offers novel delivery methods including eye drops and oral administration.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

AI-driven drug discovery just delivered a rare, first-in-class candidate with broad potential in eye disease and aging. You should explore partnerships that leverage AI to outperform existing therapies and innovate delivery methods.

◆ Coverage

1 source · 6 Aug 2026

◆ Related on Wire

◆ Topics

Biotechai-drug-designocular-diseasespreclinical-candidatenovel-targetinflammatory-disordersaging